Literature DB >> 25843297

PTEN: a yin-yang master regulator protein in health and disease.

Rafael Pulido1.   

Abstract

The PTEN gene is a tumor suppressor gene frequently mutated in human tumors, which encodes a ubiquitous protein whose major activity is to act as a lipid phosphatase that counteracts the action of the oncogenic PI3K. In addition, PTEN displays protein phosphatase- and catalytically-independent activities. The physiologic control of PTEN function, and its inactivation in cancer and other human diseases, including some neurodevelopmental disorders, is upon the action of multiple regulatory mechanisms. This provides a wide spectrum of potential therapeutic approaches to reconstitute PTEN activity. By contrast, inhibition of PTEN function may be beneficial in a different group of human diseases, such as type 2 diabetes or neuroregeneration-related pathologies. This makes PTEN a functionally dual yin-yang protein with high potential in the clinics. Here, a brief overview on PTEN and its relation with human disease is presented.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Lipid phosphatase; Neuroregeneration; Neurosurvival; Oncogenesis; PTEN; Protein tyrosine phosphatase; Tumor suppression

Mesh:

Substances:

Year:  2015        PMID: 25843297     DOI: 10.1016/j.ymeth.2015.02.009

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  20 in total

1.  A pathogenic role for germline PTEN variants which accumulate into the nucleus.

Authors:  Janire Mingo; Isabel Rodríguez-Escudero; Sandra Luna; Teresa Fernández-Acero; Laura Amo; Amy R Jonasson; Roberto T Zori; José I López; María Molina; Víctor J Cid; Rafael Pulido
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

Review 2.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

3.  The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.

Authors:  Qing Yan
Journal:  Methods Mol Biol       Date:  2022

4.  eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest.

Authors:  Luyang Han; Yuting Wu; Fangming Liu; Hongbing Zhang
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 5.  PI3K signaling in Leishmania infections.

Authors:  Peter E Kima
Journal:  Cell Immunol       Date:  2016-09-07       Impact factor: 4.868

Review 6.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

Review 7.  Cysteines as Redox Molecular Switches and Targets of Disease.

Authors:  Annamaria Fra; Edgar D Yoboue; Roberto Sitia
Journal:  Front Mol Neurosci       Date:  2017-06-06       Impact factor: 5.639

8.  Gene Expression and Correlation of Pten and Fabp4 in Liver, Muscle, and Adipose Tissues of Type 2 Diabetes Rats.

Authors:  Di Su; Chuan-Ling Zhang; Ying-Chun Gao; Xiao-Ying Liu; Cai-Ping Li; Jian Huangfu; Rui Xiao
Journal:  Med Sci Monit       Date:  2015-11-22

9.  Snail heterogeneity in clear cell renal cell carcinoma.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Rafael Pulido; Jesús M Cortés; José I López
Journal:  BMC Cancer       Date:  2016-03-08       Impact factor: 4.430

10.  Silibinin inhibits migration and invasion of the rhabdoid tumor G401 cell line via inactivation of the PI3K/Akt signaling pathway.

Authors:  Yumei Li; Chunmei Zhang; Danfeng Cai; Congde Chen; Dongmei Mu
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.